Cingulate Inc.
NCM: CINGLive Quote
📈 ZcoreAI Score
Our AI model analyzes Cingulate Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CING Z-Score →About Cingulate Inc.
Healthcare
Biotechnology
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
📊 Fundamental Analysis
Cingulate Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -450.6%, which indicates that capital utilization is currently under pressure.
At a current price of $5.76, CING currently sits at the 29th percentile of its 52-week range (Range: $3.20 - $11.89).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$66.98M
Trailing P/E
--
Forward P/E
-3.96
Beta (5Y)
-0.77
52W High
$11.89
52W Low
$3.20
Avg Volume
481K
Day High
Day Low